Literature DB >> 30021061

Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients.

Olivier Sérée1,2, Mario Altieri2,3, Elodie Guillaume2, Rémy De Mil2,4, Thierry Lobbedez5, Philip Robinson6, Philippe Segol7, Ephrem Salamé8, Armand Abergel9, Olivier Boillot10, Filomena Conti11, Olivier Chazouillères12, Maryline Debette-Gratien13, Dominique Debray14, Géraldine Hery15, Sébastien Dharancy16, François Durand17, Christophe Duvoux18, Claire Francoz17, Jean Gugenheim19, Jean Hardwigsen20, Pauline Houssel-Debry21, Emmanuel Jacquemin22, Nassim Kamar23, Marianne Latournerie24, Pascal Lebray11, Vincent Leroy25, Alessandra Mazzola11, Martine Neau-Cransac26, Georges-Philippe Pageaux27, Sylvie Radenne28, Faouzi Saliba29, Didier Samuel29, Claire Vanlemmens30, Marie-Lorraine Woehl-Jaegle31, Guy Launoy2,4, Jérôme Dumortier10.   

Abstract

De novo malignancies are one of the major late complications and causes of death after liver transplantation (LT). Using extensive data from the French national Agence de la Biomédecine database, the present study aimed to quantify the risk of solid organ de novo malignancies (excluding nonmelanoma skin cancers) after LT. The incidence of de novo malignancies among all LT patients between 1993 and 2012 was compared with that of the French population, standardized on age, sex, and calendar period (standardized incidence ratio; SIR). Among the 11,226 LT patients included in the study, 1200 de novo malignancies were diagnosed (10.7%). The risk of death was approximately 2 times higher in patients with de novo malignancy (48.8% versus 24.3%). The SIR for all de novo solid organ malignancies was 2.20 (95% confidence interval [CI], 2.08-2.33). The risk was higher in men (SIR = 2.23; 95% CI, 2.09-2.38) and in patients transplanted for alcoholic liver disease (ALD; SIR = 2.89; 95% CI, 2.68-3.11). The cancers with the highest excess risk were laryngeal (SIR = 7.57; 95% CI, 5.97-9.48), esophageal (SIR = 4.76; 95% CI, 3.56-6.24), lung (SIR = 2.56; 95% CI, 2.21-2.95), and lip-mouth-pharynx (SIR = 2.20; 95% CI, 1.72-2.77). In conclusion, LT recipients have an increased risk of de novo solid organ malignancies, and this is strongly related to ALD as a primary indication for LT.
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2018        PMID: 30021061     DOI: 10.1002/lt.25310

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

1.  Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients.

Authors:  Maria Raffaella Petrara; Sarah Shalaby; Elena Ruffoni; Martina Taborelli; Francesco Carmona; Silvia Giunco; Paola Del Bianco; Pierluca Piselli; Diego Serraino; Umberto Cillo; Riccardo Dolcetti; Patrizia Burra; Anita De Rossi
Journal:  Front Oncol       Date:  2022-06-13       Impact factor: 5.738

Review 2.  Long-term Management of the Adult Liver Transplantation Recipients.

Authors:  Narendra S Choudhary; Neeraj Saraf; Sanjiv Saigal; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-07-02

3.  De novo cancer incidence after kidney and liver transplantation: Results from a nationwide population based data.

Authors:  Boyoung Park; Junghyun Yoon; Dongho Choi; Han Joon Kim; Yun Kyung Jung; Oh Jung Kwon; Kyeong Geun Lee
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

4.  Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany.

Authors:  Kerstin Herzer; Martina Sterneck; Martin-Walter Welker; Silvio Nadalin; Gabriele Kirchner; Felix Braun; Christina Malessa; Adam Herber; Johann Pratschke; Karl Heinz Weiss; Elmar Jaeckel; Frank Tacke
Journal:  J Clin Med       Date:  2020-11-05       Impact factor: 4.241

5.  Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies.

Authors:  Zhenyu Huo; Caichen Li; Xin Xu; Fan Ge; Runchen Wang; Yaokai Wen; Haoxin Peng; Xiangrong Wu; Hengrui Liang; Guilin Peng; Run Li; Danxia Huang; Ying Chen; Ran Zhong; Bo Cheng; Shan Xiong; Weiyi Lin; Jianxing He; Wenhua Liang
Journal:  Oncoimmunology       Date:  2020-11-29       Impact factor: 8.110

Review 6.  Extrahepatic Malignancies and Liver Transplantation: Current Status.

Authors:  Narendra S Choudhary; Sanjiv Saigal; Neeraj Saraf; Arvinder S Soin
Journal:  J Clin Exp Hepatol       Date:  2020-10-24

7.  Robotic surgical system completed radical gastrectomy for gastric cancer after liver transplantation: case report and systematic review.

Authors:  Qian Chen; Junyan Fan; Junyan Liu; Chuan Li; Jiajia Liu; Feng Qian
Journal:  Transl Cancer Res       Date:  2020-06       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.